However, NOL7 expression showed no significant change during disease progression in several cancers, including cervical squamous cell carcinoma (CESC), PAAD, skin cutaneous melanoma (SKCM), and uterine corpus endometrial carcinoma (UCEC). Here, NOL7 is linked to cutaneous melanoma.